- Dexcom (NASDAQ:DXCM) initiated with a Sell rating and $57 (24% downside risk) price target at Goldman Sachs. Initiated with Neutral rating at Guggenheim. Shares down 5% premarket.
- NuVasive (NASDAQ:NUVA) initiated with Neutral rating and $47 (12% downside risk) price target at Goldman.
- Nevro (NYSE:NVRO) initiated with Neutral rating and $83 (4% downside risk) price target at Goldman.
- Hill-Rom Holdings (NYSE:HRC) initiated with Neutral rating and $85 (2% downside risk) price target at Goldman.
- ABIOMED (NASDAQ:ABMD) initiated with Buy rating and $332 (19% upside) price target at Goldman.
- Penumbra (NYSE:PEN) initiated with Buy rating and $145 (28% upside) price target at Goldman.
- Insulet (NASDAQ:PODD) initiated with Buy rating and $105 (24% upside) price target at Guggenheim.
- Adamas Pharmaceuticals (NASDAQ:ADMS) initiated with Outperform rating and $31 (26% upside) price target at Leerink.
- Senseonics Holdings (NYSEMKT:SENS) initiated with Buy rating and $6 (97% upside) price target at Guggenheim.
- Vericel (NASDAQ:VCEL) initiated with Outperform rating and $15 (55% upside) price target at Leerink.
- The Cooper Companies (NYSE:COO) resumed with Neutral rating and $231 (5% upside) price target at Goldman.
- Globus Medical (NYSE:GMED) upgraded to Buy with a $57 (16% upside) price target at Needham.
- Henry Schein (NASDAQ:HSIC) upgraded to Outperform at Leerink.
- GlaxoSmithKline (NYSE:GSK) upgraded to Outperform at Exane BNP Paribas.
- UroGen Pharma (NASDAQ:URGN) upgraded to Outperform with a $73 (22% upside) price target at Raymond James.
- AnaptysBio (NASDAQ:ANAB) downgraded to Sector Perform at RBC Capital Markets.
- Endo International (NASDAQ:ENDP) downgraded to Neutral with a $7 (22% upside) price target at Mizuho.
- PTC Therapeutics (NASDAQ:PTCT) downgraded to Underweight with $26 (flat) price target at Barclays citing lack of revenue upside. Shares down 6% premarket.